gene

NAMPT

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about NAMPT: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

577Connections

6Hypotheses

5Analyses

50Outgoing

50Incoming

5Experiments

5Debates

Summary

NAMPT is a gene implicated in neurodegeneration research. Key relationships include: regulates, associated with, inhibits. Associated with ALS, Aging, Als. Connected to 221 entities in the SciDEX knowledge graph.

View on Wiki →

No AI portrait yet

🧬 Gene Info

Gene Symbol	NAMPT
Full Name	Nicotinamide Phosphoribosyltransferase
Aliases	Nicotinamide Phosphoribosyltransferase/Visfatin
Chromosome	7q22.3
Protein Type	Enzyme
Target Class	Enzyme
Function	Small molecule competitive inhibitors of NAD+ biosynthesis enzyme
Mechanism of Action	Small molecule competitive inhibitors of NAD+ biosynthesis enzyme
Druggability	Low (0.45)
Clinical Stage	Phase II
Molecular Weight	52 kDa
Pathways	Akt, Angiogenesis, Autophagy, Cerebrovascular, Cholesterol Metabolism
UniProt ID	A0A7P0TA73
NCBI Gene ID	10135
Ensembl ID	ENSG00000105835
OMIM	608064
GeneCards	NAMPT
Human Protein Atlas	NAMPT
Associated Diseases	aging, Als, Alzheimer
Known Drugs/Compounds	NAMPT positive allosteric modulators, nicotinamide
Interactions	Actin, AGING, AKT, AMPK, AND, APOE4
SciDEX Target	View Target Profile (8 clinical trials)
SciDEX Hypotheses	TREM2 R47H Variant-Driven Metabolic Dysfunction as Metabolic NAD+ Salvage Pathway Enhancement Through
KG Connections	577 knowledge graph edges
Databases	GeneCards HPA STRING

🔮 Predicted Structure: NAMPT — AlphaFold A0A7P0TA73 Click to expand

AI-predicted structure from AlphaFold | Powered by Mol*

Wiki Pages (2)

Knowledge base pages for this entity

Canonical Page

NAMPT Gene

gene · 1368 words

→

NAMPT Protein

protein · 884 words

→

Pathway Diagram

graph TD
    NAMPT["NAMPT"] -->|"associated"| neurodegeneration["neurodegeneration"]
    NAMPT["NAMPT"] -->|"interacts"| CD38["CD38"]
    NAMPT["NAMPT"] -->|"interacts"| TLR4["TLR4"]
    NAMPT["NAMPT"] -->|"co discussed"| GPX4["GPX4"]
    NAMPT["NAMPT"] -->|"co discussed"| PLA2G6["PLA2G6"]
    NAMPT["NAMPT"] -->|"co discussed"| MMP2["MMP2"]
    CD38_1["CD38"] -->|"interacts"| NAMPT["NAMPT"]
    MMP9["MMP9"] -->|"co discussed"| NAMPT["NAMPT"]
    SLC7A11["SLC7A11"] -->|"co discussed"| NAMPT["NAMPT"]
    AQP4["AQP4"] -->|"co discussed"| NAMPT["NAMPT"]
    style NAMPT fill:#4a1a6b,stroke:#4fc3f7,stroke-width:2px,color:#e0e0e0

Outgoing (396)

Target	Relation	Type	Str
NAD salvage pathway	involved_in	pathway	0.90
SIRT1	activates	protein	0.89
Inflammatory Bowel Disease	upregulates	disease	0.85
NAD+ biosynthesis	catalyzes	pathway	0.80
Neutrophilic Inflammation	involved_in	process	0.75
Cancer	associated_with	disease	0.75
NAD+ metabolism	participates_in	pathway	0.75
Als	associated_with	disease	0.75
ferroptosis	participates_in	pathway	0.70
Mitochondrial Function	associated_with	pathway	0.70
Inflammation	activates	disease	0.65
Longevity	associated_with	disease	0.65
Stroke	regulates	disease	0.65
Tumor	inhibits	disease	0.65
Aging	expressed_in	disease	0.65
Cancer	inhibits	disease	0.65
Neurodegeneration	inhibits	disease	0.65
Addiction	therapeutic_target	disease	0.65
Aging	regulates	disease	0.65
Inflammation	associated_with	disease	0.65
Aging	inhibits	disease	0.65
Ms	inhibits	disease	0.65
Als	regulates	disease	0.65
Cancer	interacts_with	disease	0.65
Dementia	expressed_in	disease	0.65
Obesity	therapeutic_target	disease	0.65
Diabetes	therapeutic_target	disease	0.65
Alzheimer	therapeutic_target	disease	0.65
Stroke	therapeutic_target	disease	0.65
Als	activates	disease	0.65
Neurodegeneration	associated_with	disease	0.65
Neurodegeneration	activates	disease	0.65
Alzheimer	associated_with	disease	0.65
Cancer	protects_against	disease	0.65
Stroke	contributes_to	disease	0.65
Ischemia	inhibits	disease	0.65
Neurodegeneration	causes	disease	0.65
Atherosclerosis	regulates	disease	0.65
Obesity	contributes_to	disease	0.65
Cardiovascular	regulates	disease	0.65
Aging	associated_with	disease	0.65
Cancer	regulates	disease	0.65
Aging	therapeutic_target	disease	0.65
Diabetes	contributes_to	disease	0.65
Stroke	activates	disease	0.65
ALS	associated_with	disease	0.65
Cancer	activates	disease	0.65
Cancer	therapeutic_target	disease	0.65
Alzheimer	expressed_in	disease	0.65
Tumor	associated_with	disease	0.65

Incoming (181)

Source	Relation	Type	Str
h-cb833ed8	targets	hypothesis	0.90
h-var-159030513d	targets_gene	hypothesis	0.90
NAD	associated_with	gene	0.90
NAMPT positive allosteric modulators	modulates	drug	0.80
CD38	associated_with	gene	0.80
nicotinamide	targets	drug	0.75
NAD	treats	gene	0.70
APOE4	inhibits	gene	0.70
DNA	associated_with	gene	0.70
CD38	interacts_with	gene	0.64
CANCER	regulates	gene	0.60
NAD	interacts_with	gene	0.60
NEURODEGENERATION	associated_with	gene	0.60
CANCER	interacts_with	gene	0.60
NADH	associated_with	gene	0.60
NAD	inhibits	gene	0.60
INFLAMMATION	activates	gene	0.60
CANCER	inhibits	gene	0.60
NEURODEGENERATION	inhibits	gene	0.60
BCL-2	regulates	gene	0.60
GENES	regulates	gene	0.60
AGING	expressed_in	gene	0.60
AGING	causes	gene	0.60
AGING	regulates	gene	0.60
AND	regulates	gene	0.60
AND	interacts_with	gene	0.60
IL-10	inhibits	gene	0.60
AND	inhibits	gene	0.60
AGING	inhibits	gene	0.60
LGALS9	regulates	gene	0.60
MAPK	regulates	gene	0.60
NEURODEGENERATION	activates	gene	0.60
NAD	protects_against	gene	0.60
AND	protects_against	gene	0.60
CANCER	protects_against	gene	0.60
AUTOPHAGY	regulates	gene	0.60
AMPK	regulates	gene	0.60
MITOPHAGY	regulates	gene	0.60
STROKE	activates	gene	0.60
DEMENTIA	expressed_in	gene	0.60
ALZHEIMER	expressed_in	gene	0.60
APP/PS1	inhibits	gene	0.60
ALZHEIMER	associated_with	gene	0.60
WNT	associated_with	gene	0.60
NEURODEGENERATIVE DISEASES	associated_with	gene	0.60
RNA	inhibits	gene	0.60
NEURON	therapeutic_target	gene	0.60
ALZHEIMER	therapeutic_target	gene	0.60
FERROPTOSIS	inhibits	gene	0.60
CXCR4	associated_with	gene	0.60

Targeting Hypotheses (6)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
TREM2 R47H Variant-Driven Metabolic Dysfunction as the Prima	0.858	neurodegeneration	How do different microglial subtypes (DA
Metabolic NAD+ Salvage Pathway Enhancement Through NAMPT Ove	0.745	neurodegeneration	Epigenetic reprogramming in aging neuron
NAMPT-Centered NAD+ Restoration to Reverse Basal Forebrain C	0.616	neurodegeneration	Do β-amyloid plaques and neurofibrillary
NRF2-Mediated Metabolic Reprogramming: HBOT as Direct NAMPT/	0.602	neurodegeneration	View
NAMPT-SIRT1 Axis as Master Regulator of SASP-Dependent Compl	0.592	neurodegeneration	test

Combined NAMPT-Alectinib Targeting of SASP-Complement Cascad	0.549	neuroinflammation	How does Alectinib, a kinase inhibitor,

Mentioning Analyses (5)

Scientific analyses that reference this entity

Experiments (5)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Model	Status	Est. Cost
FK866 efficacy in IBD patient-derived lamina propria cells	clinical	Inflammatory bowel disease	0.950	Human IBD patient-derived LPMN	proposed	N/A
FK866 treatment in DSS-induced colitis mouse model	validation	Inflammatory bowel disease (co	0.900	DSS-induced colitis mice	proposed	N/A
NAD depletion effects on monocyte/macrophage differentiation	exploratory	Inflammatory bowel disease	0.900	Primary mouse and human monocy	proposed	N/A
FK866 in azoxymethane/DSS colitis-associated cancer model	validation	Colitis-associated cancer	0.850	AOM/DSS-treated mice	proposed	N/A
FK866 mechanism validation in Rag1-/- mice	validation	Inflammatory bowel disease	0.850	Rag1-/- mice with DSS-induced	proposed	N/A

Related Papers (5)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year
First-in-Human Phase I Study of KPT-9274, a First-in-Class Dual Inhibitor of PAK [PMID:41824279]	["Razak A", "Mahipal A", "Diamond JR", "	Target Oncol	2026
Enhancing TREM2 expression activates microglia and modestly mitigates tau pathol [PMID:40122810]	["Chen Kai", "Li Fuyao", "Zhang Shuwen",	Journal of neuroinflammation	2025
Neurodegeneration and Inflammation-An Interesting Interplay in Parkinson's Disea [PMID:33182554]	Marogianni C, Sokratous M, Dardiotis E,	International journal of molec	2020
Multiple Sclerosis Pathology. [PMID:29358320]	Lassmann H	Cold Spring Harbor perspective	2018
Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic st [PMID:25709099]	["Sampath D", "Zabka TS", "Misner DL", "	Pharmacol Ther	2015

Debates (5)

Multi-agent debates referencing this entity

Related Research

Hypotheses and analyses mentioning NAMPT in their description or question text

Combined NAMPT-Alectinib Targeting of SASP-Complement Cascade

Score: 0.549 · neuroinflammation · 2026-04-16

## Mechanistic Overview Combined NAMPT-Alectinib Targeting of SASP-Complement Cascade starts from the claim that modulat

NAMPT

Understanding Entity Pages

Summary

Wiki Pages (2)

NAMPT Gene

NAMPT Protein

Pathway Diagram

Outgoing (396)

Incoming (181)

Targeting Hypotheses (6)

Mentioning Analyses (5)

Do β-amyloid plaques and neurofibrillary tangles cause or result from cholinergi

Which specific metabolic pathways in APOE4+ microglia are most therapeutically t

Metabolic reprogramming in neurodegenerative disease

Sleep disruption as cause and consequence of neurodegeneration

Senolytic therapy for age-related neurodegeneration

Experiments (5)

Related Papers (5)

Debates (5)

The abstract explicitly questions whether AD's hallmark pathologies induce choli

While APOE4 disrupts microglial metabolism broadly, the debate didn't identify w

Senolytics targeting p16/p21+ senescent astrocytes and microglia may reduce SASP

Sleep disruption as cause and consequence of neurodegeneration

How does metabolic reprogramming (glucose metabolism shifts, brain insulin resis

Related Research

Combined NAMPT-Alectinib Targeting of SASP-Complement Cascade